Apoptosis in non-obstructive azoospermia: pathway crosstalk, cell-type vulnerability, and translational implications

Non-obstructive azoospermia (NOA) is a severe form of male-factor infertility characterized by absent spermatozoa in the ejaculate due to impaired or absent spermatogenesis. Histologically, NOA includes Sertoli-cell-only syndrome, maturation arrest, and hypospermatogenesis, each reflecting distinct patterns of germ cell depletion and residual spermatogenic potential. Apoptosis is consistently observed in impaired spermatogenesis, but its biological meaning is context dependent. In physiological spermatogenesis, apoptosis maintains germ cell homeostasis and eliminates genetically or developmentally defective cells. In NOA, excessive or misdirected apoptotic signaling may contribute to germ cell loss, Sertoli cell dysfunction, Leydig cell impairment, and collapse of the testicular microenvironment. This narrative and critical review synthesizes current evidence on apoptotic regulation in NOA, focusing on intrinsic mitochondrial pathways, extrinsic death receptor signaling, checkpoint-mediated apoptosis, oxidative stress, and pathway crosstalk within the testicular niche. We evaluate cell-type-specific vulnerability in germ cells, Sertoli cells, and Leydig cells and examine upstream regulators including genetic abnormalities, hormonal dysregulation, oxidative stress, inflammation, epigenetic alterations, varicocele, heat stress, and environmental injury. We also assess apoptosis-related and apoptosis-adjacent biomarkers for predicting sperm retrieval during testicular sperm extraction and discuss therapeutic strategies aimed at correcting upstream stressors or restoring the spermatogenic microenvironment. Current evidence supports a multi-hit model in which genetic vulnerability, endocrine dysfunction, oxidative injury, epigenetic instability, inflammation, and somatic niche failure converge to determine whether apoptosis is protective, irreversible, or potentially reversible. Future progress will require validated biomarker panels, single-cell and spatial omics, and etiology-based patient stratification before apoptosis-targeted interventions can be safely translated into routine clinical care.